hionogi & Co., Ltd. and its European subsidiary, Shionogi B.V. (hereafter "Shionogi"), today announces that its innovative antibiotic, cefiderocol, is now available in Denmark for the treatment of infections due to aerobic Gram-negative bacteria in adults (18 years or older) with limited treatment options.1
Pharmacies in Denmark are expected to place orders for cefiderocol via the online ordering portal, Serviceløsningerne (further details below).…
続きを読む